{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:34:42Z","timestamp":1790138082834,"version":"4.0.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jdcr.2025.10.074","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:30:46Z","timestamp":1764030646000},"page":"37-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Zanubrutinib for the treatment of cutaneous relapse of systemic marginal zone lymphoma: A case report"],"prefix":"10.1016","volume":"68","author":[{"given":"Selena","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jori","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2025.10.074_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00428-022-03432-2","article-title":"Follicular lymphoma and marginal zone lymphoma: how many diseases?","volume":"482","author":"Laurent","year":"2023","journal-title":"Virchows Archiv"},{"issue":"11","key":"10.1016\/j.jdcr.2025.10.074_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jdcr.2025.10.074_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1130595","article-title":"Zanubrutinib for the treatment of lymphoid malignancies: current status and future directions","volume":"13","author":"Wolska-Washer","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.10.074_bib4","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/curroncol30020135","article-title":"Management of marginal zone lymphoma: a Canadian perspective","volume":"30","author":"Peters","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jdcr.2025.10.074_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jdcr.2025.10.074_bib6","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.jdcr.2025.10.074_bib7","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.jdcr.2025.10.074_bib8","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625006514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625006514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:43:19Z","timestamp":1778931799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625006514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":8,"alternative-id":["S2352512625006514"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.074","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zanubrutinib for the treatment of cutaneous relapse of systemic marginal zone lymphoma: A case report","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}